Observational Study of Tyrosine Kinase Inhibitors for Lung Cancer with Bone Metastases
This observational study looks at how well different treatments work for non-small cell lung cancer (NSCLC) that has spread to the bones. You could be eligible if you have NSCLC with bone metastases and are between 18 and 100 years old. The study has two groups: one receiving targeted therapy called Tyrosine Kinase Inhibitors (TKIs) for specific genetic changes, and another receiving standard chemotherapy/immunotherapy along with either Zoledronic Acid (ZOMETA) or Denosumab (XGEVA) for bone disease. Researchers will measure changes in certain markers in your urine (NTX) and blood (CTX) after 3 months to see how the treatments affect your bones. This study aims to understand how these standard treatments impact bone health in patients like you.
- Study design
- This is an observational study with two groups, involving 100 planned participants. It is not a randomized or blinded study.
- What's involved
- You will have baseline and on-treatment imaging and blood tests as part of your standard care. Additionally, urine and blood bone turnover markers will be checked at baseline, 1, 3, 6, and 12 months.
- Compensation
- Not stated in the trial record.
- Follow-up
- Bone turnover markers will be checked for up to 12 months after treatment begins.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations.
At a glance
Conditions
Where it's being run
2 sites across 1 statesStudy leadership
- Erin Schenk, MD · PRINCIPAL_INVESTIGATOR · University of Colorado, Denver
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Percentage reduction of urine NTX and serum CTX3 months post-treatment
The percentage reduction in the bone turnover markers including urine N-telopeptide (NTX) and serum C-terminal telopeptide (CTX) from baseline at 3 months from starting TKI (oncogene arm) or anti-resorptive therapy as part of standard systemic therapy (non-oncogene arm).